Arlocabtagene autoleucel

N/A

Report date: 2025/02/11 14:52:38

Base Information

Drug NameArlocabtagene autoleucel
Drug Alias NameArlo-celCC-95266BMS986393BMS-986393
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsG-protein coupled receptor family C group 5member D modulators
TargetsG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesCelgene CorpJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A